Olopatadine, Ketotifen, Alcaftadine

Rapid-Acting Immunomodulators

Dual-action antihistamines combine competitive blockade of histamine receptors with intrinsic stabilization of mast cells, providing rapid improvement of pruritus and conjunctival edema in allergic conjunctivitis.

Mechanism

💊 Commercial Names

Opatanol, Patanol, Zaditen Ofta, Lastacaft, Ketotifeno Kern, Olopatadina Alcon.

🔬 Pharmacological Group

Antagonistas selectivos de receptores H₁ de histamina y estabilizadores de la membrana de mastocitos. Derivados de piridina y dibenzoxepina.

🧪 Standard Presentations

Olopatadina clorhidrato 0.1% y 0.2% (unidosis y multidosis), Ketotifeno fumarato 0.025%, Alcaftadina 0.25%.

Mechanism of Action

Estos agentes de acción integrada modulan la cascada alérgica de fase inmediata y tardía en el tejido conjuntival:

Antagonismo Selectivo de Receptores H₁: Se unen de forma competitiva a los receptores de histamina de tipo H₁ expresados en las células endoteliales de los vasos conjuntivales y en los nociceptores de las terminaciones nerviosas libres. Esto detiene de forma instantánea la vasodilatación, el incremento de permeabilidad capilar (quemosis) y el prurito intenso conjuntival.
Estabilización de Mastocitos (Células Cebadas): Inhiben de forma directa la apertura de canales de calcio dependientes de voltaje en la membrana celular del mastocito, impidiendo el influjo de calcio extracelular necesario para la polimerización de los microtúbulos y la subsiguiente exocitosis de los gránulos secretores que contienen mediadores alérgicos preformados (histamina, triptasa, quimasa).
Inhibición de la Fase Tardía de la Reacción Alérgica: Reducen la quimiotaxis y activación local de eosinófilos y neutrófilos, y detienen la liberación dural conjuntival de citocinas proinflamatorias como el ICAM-1, IL-4, IL-6 e IL-8, bloqueando la cronicidad del proceso alérgico.

Pharmacokinetics

Quantitative Ocular and Systemic Pharmacokinetics

Parameter	Olopatadine 0.2%	Ketotifen 0.025%	Alcaftadine 0.25%
Onset of Relief	Immediate in 10 - 15 minutes.	Immediate in 15 minutes.	Immediate in 3 minutes (The fastest in his group).
Duration of Effect	Up to 12 - 24 hours (allows dosage of 1 dose per day).	Up to 12 hours of dural symptomatic relief.	Up to 24 hours of conjunctival allergic protection.
Clearance and Metabolism	Low systemic absorption; It is excreted mainly unchanged by the kidney.	Inactive secondary phase I hepatic metabolism.	Metabolism by demethylation to prolonged secondary active metabolite.
Half-life (t_1/2)	t_1/2 in plasma ≈ 3 - 4 hours.	t_1/2 plasma ≈ 12 hours.	t_1/2 plasma ≈ 30 minutes (metabolite: 2 hours).

Security

Contraindications

Absolute: Documented hypersensitivity to the active salt or any of the components of the eye drops.
Relative: Use of soft contact lenses during instillation (the preservative benzalkonium chloride is absorbed into the hydrogel of the lens, causing irreversible discoloration of the lens and inducing delayed corneal epitheliotoxicity; it should be advised to remove the lenses and wait at least 15-20 minutes before inserting them).

Adverse Effects (ADR)

Ocular Sites: Mild transient burning or stinging sensation post-dosage; dry eye due to slight secondary muscarinic blockade activity; superficial punctate keratitis; transient tearing and blurred vision.
Systemic: Mild tension headache, asthenia, dryness of the nasal mucosa and mild hyposmia. No or negligible central sedation compared to classic first-generation systemic antihistamines.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousNepafenac, Ketorolac, Bromfenac NextCiclosporin A, Lifitegrast

System: Ophthalmology
Cluster: Rapid-Acting Immunomodulators

Download Epistemis